



FOCUS ON PHARMACOLOGY

Behavior Medications: Which Medication, Which Patient?

Karen L. Overall, MA, VMD, PhD, DACVB
University of Pennsylvania

shutterstock.com/Anna Hoychuk

The best treatment approaches in veterinary behavioral medicine are often multimodal. At the core of state-of-the-art multimodal treatment is smart, rational, and effective use of behavioral medication. Which medication do you choose for which condition, how do you know if it is working, what are the risks, and what advantages might you gain for your patient by combining medications?

The keys to effective treatment of behavioral problems are no different than for somatic medical problems:

- Identify the constellation of relevant signs/changes.
- Nest these within a diagnosis or diagnoses.
- Understand the factors that contribute to the development and maintenance of the diagnosis.
- Use your treatment to modulate these factors in a manner that can be measured and tracked by alterations in the clinical signs and profile.

Unfortunately, practitioners often feel helpless in the face of behavioral complaints because the signs seem so nonspecific. As is true in internal medicine, relevant clinical signs in behavioral medicine are not specific, but too few veterinarians are taught

to recognize and quantify behavioral signs and to do so as part of routine evaluation. As for all other conditions in veterinary medicine, the best and most successful treatment is early treatment. The earlier appropriate behavioral medication is prescribed, the less the patient will suffer from fear, anxiety, or aggression and the cognitive and social changes that result from these pathologic conditions.

A helpful approach to understanding the thought process involved in choosing medications is to consider practical diagnostic examples, review the signs exhibited in these examples and the regions of the brain involved, and review effects of medications on those regions and on neurochemicals affecting these regions. An advantage of this approach is that the clinical signs provide a baseline against which targeted signs can be assessed for response to medication and other treatment.

RECOGNIZING CLINICAL SIGNS AND COMORBID CONDITIONS

Consider patients with 2 common behavioral diagnoses: separation anxiety and noise reactivity

phob
condi
disor
condi
veteri
appoi
assess
Resul
shoul
wheth
Signs
and te
indivi
report
excess
appare
for the
pantin
signs c
becaus
but do
profou
obviou

Dogs t
noises
for a n
"reacti
for wor
the mil
any his
insist t
it pants
by hidi
are suff

Video i
and an
to medi

CHOC
ACCC
PRES

When c
separati
practic
in relev
be affect

phobia. These are commonly comorbid conditions,¹ as is the rule among anxiety disorders.^{2,3} Because the development of both conditions ranges from subtle to explosive, veterinarians should screen for them at each appointment using a standardized clinical assessment tool⁴ to identify and treat them early. Results of these routine clinical assessments should be recorded and evaluated to determine whether they meet diagnostic criteria (**Box 1**). Signs of distress should be evaluated in currency and terminology that are meaningful for the individual patient because the most commonly reported behaviors (elimination, destruction, excessive vocalization) are only the most readily apparent and easily recognizable signs of anxiety for the clients and veterinary team. Drooling, panting, freezing, withdrawal, and cognitive signs of anxiety are less commonly diagnosed because they are less apparent to people, but dogs displaying them may be even more profoundly affected than dogs that show more obvious signs (**Box 2** lists signs of anxiety).

Dogs that are distressed when exposed to noises or storms but do not meet the criteria for a noise phobia may best be classified as “reactive” and assessed for treatment. The risk for worsening in these dogs is nontrivial. Even the mildest signs should be treated if a dog has any history of reacting to noises.⁶ Clients may insist that they can simply hold the dog while it pants and shakes or that the dog calms itself by hiding in the closet. In fact, these patients are suffering and need behavioral medication.

Video is a powerful tool for accurate diagnosis and an even better way to assess response to medication and other treatment.

CHOOSING MEDICATIONS ACCORDING TO PATIENT PRESENTATION

When choosing medication for patients with separation anxiety, noise reactivity, or both, practitioners should be guided by expected changes in relevant signs, regions of the brain that may be affecting those signs, and distributions of

neurochemical receptors in the regions that may be affected by the medication chosen. Some dogs show suites of correlated behaviors; for example, salivation appears to be more common in dogs that freeze and become immobile. If we alter the salivation, do we alter any part of the feedback system that maintains the anxiety? In fact, by

BOX 1. Diagnostic Criteria for Common Behavioral Disorders⁵

Separation anxiety

Behavioral condition resulting in the following signs of distress exhibited by the patient only in the absence of, or lack of access to (a virtual absence), the client:

- Physical (injury, uneven nail wear, scored teeth)
- Physiologic (salivation, increased heart rate)
- Behavioral, cognitive, or emotional (social withdrawal, agitation, lack of focus)

Noise phobia

- Behavioral abnormality resulting in profound, nongraded, extreme response to noise, manifested as intense avoidance, escape, or anxiety, associated with sympathetic nervous system signs.
- Dogs can shut down and freeze or run without caution.
- Decreased sensitivity to pain or social stimuli is often concomitant.
- Once established, repeated exposure results in an invariant pattern of response, but not all dogs show a full-blown invariant response.

Panic disorder/panic

- Behavioral abnormality resulting in a sudden, all-or-nothing, profound, abnormal response that results in extremely fearful behaviors (catatonia, mania, escape) where the provocative stimulus may be unknown/unclear, situational, internal, and/or generalized.
- Differs from conditions involving phobias, where the provocative stimulus is more discrete and identifiable, and where the level of distress characteristic of panic may not be achieved.
- The term *panic disorder* should be restricted to a described pattern of like events.
- A *panic event* is a singular or infrequent event where the patient exhibits these behaviors, but the data are insufficient to determine whether the consistent pattern exists as required for panic disorder.
- The risk that a patient will experience another panic event after having had one is great.

affecting salivation we may affect related regions of the amygdala associated with distress.⁷

Medications commonly used to treat fears, anxieties, and aggression in dogs are listed in **Table 1**. Many other medications used to treat some aspect of behavioral abnormalities are beyond the scope of this article and so are not discussed here (but see Overall 2013⁵).

Table 1 compares many of these medications, by class, with respect to their effects on noradrenaline/norepinephrine (NA/NE) and serotonin (5-HT) receptors and sedation and

anticholinergic effects. **Table 2** indicates the relative effects of these medications on receptor classes.

CONSIDERING RISK FACTORS

Because so many behavioral conditions are comorbid or have wildly different behavioral presentations within a diagnosis (eg, dogs with noise phobia can freeze and hide or may run and destroy in panic), the best approach is probably one that allows combination of medications to address the neurochemical profile of the behavioral abnormality but minimizes somatic risk. **Box 3** provides a general model for such an approach.

BOX 2. Common Nonspecific Signs of Anxiety⁵

- Urination
- Defecation
- Anal sac expression
- Panting
- Increased respiration and heart rates
- Trembling/shaking
- Muscle rigidity (usually with tremors)
- Lip licking
- Nose licking
- Grimace (retraction of lips)
- Head shaking
- Smacking or popping lips/jaws together
- Salivation/hypersalivation
- Vocalization (excessive and/or out of context); often frequent repetitive sounds (including high-pitched whines, like those associated with isolation)
- Yawning
- Immobility/freezing or profoundly decreased activity
- Pacing and profoundly increased activity
- Hiding or hiding attempts
- Escaping or escape attempts
- Body language of social disengagement (turning head or body away from signaler)
- Lowering of head and neck
- Inability to meet a direct gaze
- Staring at some middle distance
- Body posture lower (in fear, the body is extremely lowered and tail tucked)
- Ears lowered and possibly droopy because of changes in facial muscle tone
- Mydriasis
- Scanning
- Hypervigilance/hyperalertness (may be noticed only when dog or cat is touched or interrupted; animal may hyperreact to stimuli that otherwise would not elicit this reaction)
- Shifting legs
- Lifting paw in an intention movement
- Increased closeness to preferred associates
- Decreased closeness to preferred associates
- Profound alterations in eating and drinking (acute stress is usually associated with decreases in appetite and thirst; chronic stress is often associated with increases)
- Increased grooming, possibly with self-mutilation
- Decreased grooming
- Possible appearance of ritualized or repetitive activities
- Changes in other behaviors, including increased reactivity and increased aggressiveness (may be nonspecific)

Most of these medications are metabolized through the cytochrome P-450 system.

Table 3 lists inducers and inhibitors that affect how these behavioral compounds are metabolized. Understanding such P-450 enzyme system interactions allows medication adjustment to minimize adverse events. Although most available information is for humans, some studies have measured CYP effects for dogs,¹¹⁻¹⁴ with particularly strong conservation for CYP 1A enzymes. Isoforms are sufficiently similar between humans and dogs that inference from human information may serve as a good precaution.

TAILORING THERAPY: CLINICAL EXAMPLES

Applying an approach that seeks to tailor treatment in behavioral medicine to specific presentations and targeted signs is not difficult but does require thought.

Separation Anxiety

A dog with separation anxiety that involves salivation will benefit from any anticholinergic agent because the undesirable effect may be part of a reinforcing feedback cycle. Medications classified as anticholinergics are not used in

TABLE 1 Relative Effects of Medications on Noradrenaline/Norepinephrine and Serotonin Receptors and for Sedation or Anticholinergic Effects⁸⁻¹⁰

PARENT COMPOUND	NA/NE	5-HT	POTENTIAL FOR SEDATION	POTENTIAL FOR ANTICHOLINERGIC EFFECTS
TCA s				
Imipramine	+++	++	Moderate	Moderate
Amitriptyline	++	++	High	High
Nortriptyline	+	+	Moderate	Moderate
Clomipramine	++	+++	High	High
SSRI s				
Fluoxetine	+	+++	Moderate	Low
Paroxetine		++	High	High
Sertraline	+	+++	Moderate	Moderate
Fluvoxamine		+++	Moderate	
Citalopram		+++	Moderate	Moderate
SARI s				
Trazodone		++	High	Low
Benzodiazepines				
Alprazolam			Low to moderate	
Lorazepam			Low to moderate	
Diazepam			High	
Clonazepam			Moderate	
α-Agonists				
Clonidine			Moderate	
OTM dexmedetomidine			Low	

+, some effect; ++, moderate effect; +++, large effect; 5HT, 5-hydroxytryptamine (serotonin); NA/NE, noradrenaline/norepinephrine; OTM, oral transmucosal; SARI, serotonin antagonist/reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

veterinary medicine; however, many medications have anticholinergic effects as part of their pharmacologic profile. Anticholinergic effects are common for many tricyclic antidepressants (TCAs), and although they have the potential for undesirable events, in this example, a medication with some anticholinergic effect may be beneficial.

Additionally, a region in the central nucleus of the amygdala contributes to salivation, suggesting that medications that affect serotonin and norepinephrine regulation will be useful.

Accordingly, amitriptyline or clomipramine may be rational choices, but clomipramine comes in a canine form (Clomicalm) with scored tablets, is a relatively more specific compound because of its

intermediate metabolites, and affects a wide range of receptor types. It may be a good choice here. If the dog is vocalizing or blocks or destroys doors through which clients leave, the behaviors are associated with affiliation and social needs and loss. A medication that has a profound effect on 5HT receptors, especially the 5-HT_{1A} receptors that are involved in social anxieties, may benefit the patient.

Unfortunately, medication costs and formulations change frequently. What do we do if clients cannot afford or obtain any formulation of clomipramine, a particular problem in the United States in the past few years? By reverting to the idea that distress about absences lies at the core of separation anxiety, pick a selective serotonin reuptake inhibitor (SSRI) affecting the 5-HT_{1A} receptor because this receptor

TABLE 2 Relative Medication Effects on Most Common Receptors (Antagonist Role Unless Otherwise Specified)⁸⁻¹⁰

PARENT COMPOUND	5-HT 1A	5-HT 1B	5HT1D	5HT2A	5-HT 2B	5-HT 2C	5-HT 3	α1A	α 2A	α 1B	α 2B	D1	D2	H1 ^a	ACh
TCAs															
Imipramine				++		++		++						+++	+++
Amitriptyline	+			+++		+++		+++						+++	+++
Nortriptyline	+			+++		+++		+++						+++	+++
Clomipramine				+++		+++	+++	+++				+	++	+++	+++
SSRIs															
Fluoxetine	+++	+	+	+	+	++	+	+				+			
Paroxetine	++													+	+++
Sertraline	+++							+++							
Fluvoxamine ^b															
Citalopram	+++														
SARIs															
Trazodone	++			+++		+		+						+	
α-Agonists															
Clonidine								+	+	++	+++				
OTM dexmedetomidine									+++						
β-blockers/antagonists															
Propranolol										++	++				
Pindolol										++	++				

+, some effect; ++, moderate effect; +++, large effect; ACh, acetylcholine; SARI, serotonin antagonist/reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

^aPotency at the H1 receptor correlates with weight gain in humans.⁹

^bPrimarily affects transporters.

has been widely experimentally associated with social anxieties. If broader coverage is needed, combine it with a less specific TCA (amitriptyline, nortriptyline) and lower the dosage of both.

Separation Anxiety Plus Noise Reactivity

What are the concerns if the patient also reacts badly to noises? Here, we need to distinguish between panicking and being distressed (**Box 1**). If the dog is distressed, any of the benzodiazepines may lower its reactivity level by providing central inhibition of responses. Benzodiazepines can be calming agents, antianxiety agents, or sedative and analgesic agents, depending on dose, route, and choice of medication. Alprazolam is considered the only truly “panicolytic” benzodiazepine. These compounds should not be used to treat patients in households where humans have addiction or substance abuse difficulties.

Dogs that are distressed about noise or departures may respond to lorazepam and become calmer, while others may need longer-lasting benzodiazepines (diazepam, clonazepam), which may also make them sleep more. Additional and deeper sleep may not always be an adverse

or sedative effect of a behavioral medication, but with long-term use benzodiazepines can disrupt natural sleep rhythms. This is not a major concern for short-term treatment.

Anxious dogs likely have interrupted sleep cycles; clients often say they notice that once the dog begins to respond to medication, the dog sleeps longer or more deeply. Good, restorative sleep should be a treatment goal. In contrast, excessive sedation, including persistent cognitive impairment, lack of motor coordination, or paradoxical excitement, is an undesired effect. The key with benzodiazepines is finding the right dose for the patient; these medications have highly variable effects. Having clients test benzodiazepines for adverse events, such as excessive sedation or paradoxical excitation, when no stimulation is expected is an important step. If no adverse effects are observed, clients should then help test and record the effects of increasing dosages to see if they can find one that provides relief.

Clonidine, an α_2 agonist, may also aid distressed dogs by decreasing both central and peripheral signs of sympathetic arousal. At higher dosages, clonidine can be both sedative (impairing cognition) and hypotensive (rendering patients

BOX 3. Sample Combinations of Medications That May Allow Dosage of Each to Be Lowered With Enhanced Efficacy⁵

- Amitriptyline (TCA) [anxiety-related diagnosis] + fluoxetine (SSRI) [anxiety-related diagnosis]
- Amitriptyline (TCA) [anxiety-related diagnosis] + fluoxetine (SSRI) [anxiety-related diagnosis] + alprazolam (BZD) [panic/phobia/severe distress with known trigger]
- Amitriptyline (TCA) [anxiety-related diagnosis] + alprazolam (BZD) [panic/phobia]
- Fluoxetine (SSRI) [anxiety-related diagnosis] + alprazolam (BZD) [panic/phobia]
- Clomipramine (TCA, relatively specific) [anxiety-related diagnosis] + alprazolam (BZD) [panic/phobia]
- Clomipramine (TCA, relatively specific) [anxiety-related diagnosis] + diazepam (BZD) [panic/phobia]—could be fairly sedating
- Amitriptyline (TCA) [anxiety-related diagnosis] + diazepam (BZD) [panic/phobia]—could be fairly sedating
- Paroxetine (SSRI) (social anxiety) + alprazolam (BZD) [panic/appetite stimulation in cats]

BZD, benzodiazepine; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.

TABLE 3 Behavioral Medications That Act as Substrates to Inhibit or Induce the CYP Enzyme in Humans

P-450 ENZYME	SUBSTRATE	INHIBITOR	INDUCER
CYP 1A2	TCAs Fluvoxamine Mirtazapine Duloxetine	Fluvoxamine Fluoxetine Paroxetine Sertraline Some TCAs Fluoroquinolones ^a	Phenobarbital ^a Carbamazepine ^a Phenytoin ^a
CYP 2A6			Barbiturates ^a
CYP 2B6			Phenobarbital ^a
2 CYP C9/ CYP 2C9/10	Sertraline Fluoxetine Amitriptyline	Fluvoxamine Fluoxetine Sertraline Fluconazole ^a Sulfaphenazole ^a	Carbamazepine ^a Phenobarbital ^a Phenytoin ^a
2C19/CYP 2C19	Citalopram Sertraline Clomipramine Imipramine	Fluvoxamine Fluoxetine Sertraline Omeprazole ^a	Carbamazepine ^a
CYP 2D6	Fluoxetine Fluvoxamine Citalopram Duloxetine Paroxetine Venlafaxine Trazodone Nefazodone TCAs	Duloxetine Fluoxetine Paroxetine Norfluoxetine Citalopram Sertraline Some TCAs	
CYP 2E1			
CYP 3A4	Nefazodone Sertraline Venlafaxine Trazodone TCAs	Fluvoxamine Norfluoxetine TCAs, barbiturates Dexamethasone/long-term glucocorticoids Phenytoin St. John's wort ^b Flucloxacillin Nefazodone ^a Fluconazole ^a Ketoconazole ^a Cimetidine ^a Macrolides: clarithromycin, erythromycin ^a Propofol	Carbamazepine ^a Barbiturates ^a Dexamethasone/long-term glucocorticoids ^a Phenytoin ^a St. John's wort ^{a,b} Flucloxacillin ^a

Inducers slow the rate at which the substrate medication is available and lower the amount available. Inhibitors increase the rate at which the substrate medication is available and increase the amount available. There are few detailed studies for dogs, but the patterns identified to date do not deviate from these, so consideration should be given to monitoring patients carefully when medications from these classes are combined. TCA, tricyclic antidepressant. Adapted from Overall.⁵

^aMedications used for nonbehavioral conditions.

^bHyperforin is the compound that is the inducer.

unstable on stairs or as they move through complex environments). If these effects appear, lowering the dose may ameliorate them.

Trazodone, a serotonin antagonist/reuptake inhibitor (SARI), may help the dog to calm its activity level because the main effect of this drug is a slightly sedative one—trazodone increases sleep time,^{15–17} and its receptor profile (5-HT_{A/B} antagonist, partial 5-HT_{1A} agonist) is consistent with this.

Panic

If the dog is panicking, there are 2 additional suitable choices. The first, alprazolam, can be given before or during the distressing event. In fact, if it is given regularly (usually q12h but up to q6h) before anticipated events, it can raise the threshold for reaction but provide central inhibitory effects, as well as peripheral effects on muscle tension that may accompany and provide a positive feedback response associated with panic.

The second choice is dexmedetomidine, which has anxiolytic, sedative, analgesic, and sympatholytic properties.¹⁸ As an oral transmucosal (OTM) gel (Sileo; zoetisus.com), it has no first-pass effects; instead, it directly exerts agonist effects on presynaptic α_2 receptors in the locus ceruleus. The locus ceruleus is the region of the brainstem that gives rise to all NA/NE brain tracts and is where sympathetic arousal may originate and is modulated. In essence, this region is the source of anticipatory anxiety and arousal. Accordingly, without involving the CYP 450 enzyme system, OTM dexmedetomidine may have profound panicolytic effects and may prevent and/or modulate the arousal that makes it so difficult for humans to use any behavioral or environmental management strategies or for dogs to use any operant or cognitive-behavior management skills they may have learned.

Nausea

With both separation anxiety and noise phobia/reactivity, dogs may feel nauseous. Distressed dogs cannot eat because of antagonism of

parasympathetic effects due to sympathetic arousal. However, the distress itself may contribute to nausea. For dogs that retch, salivate, chew on nonfood substances, have diarrhea before or after the event, stop eating before the event, and take a long time to eat after the event, we should consider whether maropitant (Cerenia; cereniadv.com), the neurokinin 1 receptor antagonist/substance P blocker, could be beneficial. This compound may have a role in directly treating aspects of depression, fear, and anxiety¹⁹ but may be helpful for the more immediate gastrointestinal effects that may be associated with distress.

In dogs with combined abnormalities that cause them to react to noise and absences, medications from 2 to 4 classes may need to be combined to achieve maximal resolution of signs. As to be expected from the patterns of receptor response, when medications that share a direct mechanism of action and/or a potential adverse effect are combined (eg, sedation, shared CYP 450 enzymes), dosages should be lowered. Occasionally, frequencies may be altered, rather than dosages lowered, depending on the dog's response. If 2 medications that are combined both affect serotonin, reduce the dose of both to minimize the risk for serotonin syndrome. This condition is rare and usually idiopathic, and data in dogs are lacking; however, it can be tragic. Although not discussed here, monoamine oxidase inhibitors (eg, selegiline) should not be combined with TCAs, SSRIs, or SARIs.

SUMMARY

Behavioral medicine and neuroscience are about pattern recognition. This brief introduction to thinking in a neurobehavioral mechanistic manner is intended to introduce clinicians to how to recognize and use relevant patterns for the benefit of the patients. We are learning more about genetic and functional patterns daily, and new applications for medications may result. By using the tables in this article to inform medication choice and to become comfortable with a few different treatment combinations, clinicians can make great improvements in their patients' mental health and in everyone's quality of life. **TVP**

TRIFEXIS®
(spinosad + milbemycin oxime)
Chewable Tablets

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Before using TRIFEXIS chewable tablets, please consult the product insert, a summary of which follows:

Indications:
TRIFEXIS is indicated for the prevention of heartworm disease (*Dirofilaria immitis*). TRIFEXIS kills fleas and is indicated for the prevention and treatment of flea infestations (*Ctenocephalides felis*), and the treatment and control of adult hookworm (*Ancylostoma caninum*), adult roundworm (*Toxocara canis* and *Toxascaris leonina*) and adult whipworm (*Trichuris vulpis*) infections in dogs and puppies 8 weeks of age or older and 5 pounds of body weight or greater.

Dosage and Administration:
TRIFEXIS is given orally, once a month at the minimum dosage of 13.5 mg/lb (30 mg/kg) spinosad and 0.2 mg/lb (0.5 mg/kg) milbemycin oxime body weight. For heartworm prevention, give once monthly for at least 3 months after exposure to mosquitoes (see **EFFECTIVENESS**).

Contraindications:
There are no known contraindications to the use of TRIFEXIS.

Warnings:
Not for human use. Keep this and all drugs out of the reach of children. Serious adverse reactions have been reported following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS (see **ADVERSE REACTIONS**).

Precautions:
Treatment with fewer than 3 monthly doses after the last exposure to mosquitoes may not provide complete heartworm prevention (see **EFFECTIVENESS**).

Prior to administration of TRIFEXIS, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms. TRIFEXIS is not effective against adult *D. immitis*. While the number of circulating microfilariae may decrease following treatment, TRIFEXIS is not indicated for microfilariae clearance. Mild, transient hypersensitivity reactions manifested as labored respiration, vomiting, salivation and lethargy, have been noted in some dogs treated with milbemycin oxime carrying a high number of circulating microfilariae. These reactions are presumably caused by release of protein from dead or dying microfilariae.

Use with caution in breeding females. The safe use of TRIFEXIS in breeding males has not been evaluated.

Use with caution in dogs with pre-existing epilepsy (see **ADVERSE REACTIONS**). Puppies less than 14 weeks of age may experience a higher rate of vomiting.

Adverse Reactions:
In a well-controlled US field study, which included a total of 352 dogs (176 treated with TRIFEXIS and 176 treated with an active control), no serious adverse reactions were attributed to administration of TRIFEXIS. All reactions were regarded as mild.

Over the 180-day study period, all observations of potential adverse reactions were recorded. Reactions that occurred at an incidence >1% (average monthly rate) within any of the 6 months of observation are presented in the following table. The most frequently reported adverse reaction in dogs in the TRIFEXIS group was vomiting.

Average Monthly Rate (%) of Dogs With Adverse Reactions

Adverse Reaction	TRIFEXIS Chewable Tablets*	Active Control Tablets*
Vomiting	6.13	3.08
Pruritus	4.00	4.91
Lethargy	2.63	1.54
Diarrhea	2.25	1.54
Dermatitis	1.47	1.45
Skin Reddening	1.37	1.26
Decreased appetite	1.27	1.35
Pinna Reddening	1.18	0.87

*n=176 dogs
In the US field study, one dog administered TRIFEXIS experienced a single mild seizure 2 1/2 hours after receiving the second monthly dose. The dog remained enrolled and received four additional monthly doses after the event and completed the study without further incident.

Following concomitant extra-label use of ivermectin with spinosad alone, a component of TRIFEXIS, some dogs have experienced the following clinical signs: *trembling/twitching, salivation/drooling, seizures, ataxia, mydriasis, blindness and disorientation*. Spinosad alone has been shown to be safe when administered concurrently with heartworm preventatives at label directions. In US and European field studies, no dogs experienced seizures when dosed with spinosad alone at the therapeutic dose range of 13.5-27.3 mg/lb (30-60 mg/kg), including 4 dogs with pre-existing epilepsy. Four epileptic dogs that received higher than the maximum recommended dose of 27.3 mg/lb (60 mg/kg) experienced at least one seizure within the week following the second dose of spinosad, but no seizures following the first and third doses. The cause of the seizures observed in the field studies could not be determined. For technical assistance or to report suspected adverse drug events, contact Elanco Animal Health at 1-888-545-5973. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or <http://www.fda.gov/AnimalVeterinary/SafetyHealth>

Post Approval Experience (Mar 2012):
The following adverse reactions are based on post-approval adverse drug event reporting. The adverse reactions are listed in decreasing order of frequency: vomiting, depression/lethargy, pruritus, anorexia, diarrhea, trembling/shaking, ataxia, seizures, hypersalivation, and skin reddening.

Effectiveness:

Heartworm Prevention:
In a well-controlled laboratory study, TRIFEXIS was 100% effective against induced heartworm infections when administered for 3 consecutive monthly doses. Two consecutive monthly doses did not provide 100% effectiveness against heartworm infection. In another well-controlled laboratory study, a single dose of TRIFEXIS was 100% effective against induced heartworm infections. In a well-controlled six-month US field study conducted with TRIFEXIS, no dogs were positive for heartworm infection as determined by heartworm antigen testing performed at the end of the study and again three months later.

Flea Treatment and Prevention:
In a well-controlled laboratory study, TRIFEXIS demonstrated 100% effectiveness on the first day following treatment and 100% effectiveness on Day 30.

In a well-controlled laboratory study, spinosad, a component of TRIFEXIS, began to kill fleas 30 minutes after administration and demonstrated 100% effectiveness within 4 hours. Spinosad, a component of TRIFEXIS, kills fleas before they can lay eggs. If a severe environmental infestation exists, fleas may persist for a period of time after dose administration due to the emergence of adult fleas from pupae already in the environment. In field studies conducted in households with existing flea infestations of varying severity, flea reductions of 98.0% to 99.8% were observed over the course of 3 monthly treatments with spinosad alone. Dogs with signs of flea allergy dermatitis showed improvement in erythema, papules, scaling, alopecia, dermatitis/pyodermitis and pruritus as a direct result of eliminating the fleas.

Treatment and Control of Intestinal Nematode Infections:
In well-controlled laboratory studies, TRIFEXIS was ≥ 90% effective in removing naturally and experimentally induced adult roundworm, whipworm and hookworm infections.

Palatability:
TRIFEXIS is a flavored chewable tablet. In a field study of client-owned dogs where 175 dogs were each offered TRIFEXIS once a month for 6 months, dogs voluntarily consumed 54% of the doses when offered plain as if a treat, and 33% of the doses when offered in or on food. The remaining 13% of doses were administered like other tablet medications.

NADA 141-321, Approved by the FDA
Manufactured by Elanco Animal Health, A Division of Eli Lilly & Company
Indianapolis, IN 46285
www.trifexis.com

Elanco, Trifexis and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Sep 2014 03B049_Mk04



Karen L. Overall

Karen L. Overall, MA, VMD, PhD, DACVB, is a senior research scientist in the Biology Department at the University of Pennsylvania. She received her VMD degree from the University of Pennsylvania and her PhD from the University of Wisconsin-Madison. She did her residency training in veterinary behavioral medicine at the University of Pennsylvania. She has served on the faculties of both the veterinary and medical schools at the University of Pennsylvania and ran the Behavior Clinic at Penn Vet. Dr. Overall has been named the North American Veterinary Conference Small Animal Speaker of the Year. Her research focuses on neurobehavioral genetics of dogs, the development of normal and abnormal behaviors, and how behavior is assessed, especially as concerns working dogs.

References

- Overall KL, Dunham AE, Frank D. Frequency of nonspecific clinical signs in dogs with separation anxiety, storm/thunderstorm phobia, and noise phobia, alone or in combination. *JAVMA* 2001;219(4):467-473.
- Tiira K, Lohi H. Early life experiences and exercise associate with canine anxieties. *PLoS One* 2015;10(11):e0141907.
- Tiira K, Sulkama S, Lohi H. Prevalence, comorbidity, and behavioral variation in canine anxiety. *J Vet Behav Clin Appl Res* 2016;16:36-44.
- Hammerle M, Horst C, Levine E, et al. AAHA 2015 Canine and Feline Behavior Management Guidelines. aaha.org/professional/resources/behavior_management_guidelines.aspx. Accessed November 2016.
- Overall KL. *Manual of Clinical Behavioral Medicine for Dogs and Cats*. St. Louis, MO: Elsevier; 2013.
- Overall KL, Tiira K, Broach D, Bryant D. Genetics and behavior: a guide for practitioners. *Vet Clin North Am Small Anim Pract* 2014;44(3):483-505.
- Davis M. Neurobiology of fear responses: the role of the amygdala. *J Neuropsychiatry Clin* 1997;9(3):382-402.
- Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. *Psychopharmacology (Berl)* 1994;114(4):559-565.
- Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. *Br J Pharmacol* 2007;151(6):737-748.
- Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. *Eur J Pharmacol* 1997;340(2-3):249-258.
- Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and inductions. *Expert Opin Drug Metab Toxicol* 2006;2(6):875-894.
- Bogaards JJP, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. *Xenobiotica* 2000;30(12):1131-1152.
- Turpeinene M, Ghicic C, Opritou M, et al. Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. *Xenobiotica* 2007;37(12):1367-1377.
- Van Beusekom CD, Schipper L, Fin-Gremmels J. Cytochrome P450-mediated hepatic metabolism of new fluorescent substrates in cats and dogs. *J Vet Pharmacol Ther* 2010;33(6):519-527.
- Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. *Drugs Aging* 1994;4(4):331-55.
- Gruen ME, Sherman BL. Use of trazodone as an adjunctive agent in the treatment of canine anxiety disorders: 56 cases (1995-1997). *JAVMA* 2008;233(12):1902-1907.
- Gilbert-Gregory SE, Stull JW, Rice MR, Herron ME. Effects of trazodone on behavioral signs of stress in hospitalized dogs. *JAVMA* 2016;249(11):1281-1291.
- Gertler R, Brown HC, Mitchell DH, Silvius EN. Dexmedetomidine: a novel sedative-analgesic agent. *BUMC Proc* 2001;14:13-21.
- Varty GB, Cohen-Williams ME, Hunter JC. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. *Behav Pharmacol* 2003;14(1):87-95.